Stratec (SBS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
8 Sep, 2026Executive summary
Business performance improved significantly in Q2 2026, narrowing the year-on-year gap in sales and earnings by the end of H1 2026, with strong momentum in the system business and robust free cash flow.
Profitability for H1 2026 nearly matched the prior year, supported by cost discipline and strong demand for lifecycle management projects.
FY 2026 guidance confirmed, with growth expected from strong year-end business volumes and a backend-loaded year.
High customer demand for lifecycle management projects and successful transfer of new developments to series production.
Cost discipline and structural adjustments are in place to maintain profitability.
Financial highlights
H1 2026 revenues were €112.5 million, a nominal decline of 5.1% (3.3% constant currency).
Adjusted EBITDA was €15.7 million (margin 13.9%), and adjusted EBIT was €7.7 million (margin 6.9%), both nearly matching prior year levels.
Free cash flow improved to €23.5 million from negative €14.7 million last year.
Adjusted net income was €4.1 million (EPS €0.34); reported IFRS net income was €2.4 million (EPS €0.20).
Operating cash flow was €29.7 million, up from negative €5.8 million in the prior year.
Outlook and guidance
Full-year 2026 sales guidance confirmed: medium to high single-digit percentage growth at constant currency.
Adjusted EBIT margin for the year expected around 10%, with investments at the lower edge of the 6.5%-8.5% of sales range.
Growth is expected to be heavily backend-loaded, with Q4 contributing up to 35% of annual sales.
2025-2028 CAGR expected at 6%-8%; 2028-2030 CAGR expected at 10%-12%. Adjusted EBIT margin targets: at least 13% by 2028, 15% by 2030.
Workforce expected to remain stable or expand slightly.
Latest events from Stratec
- Strong recurring revenues, robust growth targets, and ambitious ESG goals drive future outlook.SBS
Investor presentation - Q1 2026 sales and margins fell, but cash flow improved; growth targets and ESG goals remain strong.SBS
Corporate presentation - Sales declined in Q1 2026, but strong cash flow and a robust growth pipeline support future targets.SBS
Investor presentation - Sales and margins fell, but free cash flow surged and 2026 guidance was reaffirmed.SBS
Q1 2026 - Stable 2025 sales and margins, strong Q4 systems growth, and positive long-term outlook.SBS
Q4 2025 - Recurring revenue dominates as growth resumes in 2025, driven by innovation and M&A focus.SBS
Health Care Conference - Sales down 6.1% Y/Y; margins stable; Q4 rebound expected from new orders and deliveries.SBS
Q3 2024 - Margins and cash flow improved despite lower sales; 2024 guidance remains unchanged.SBS
Q2 2024 - Stable margins and recurring revenues support growth as innovation and M&A drive recovery.SBS
43rd Annual J.P. Morgan Healthcare Conference 2025